1 Supplementary Table 1. Response rate according to the C2D1/Baseline ratio

|  | Total <br> $(\mathrm{n}=52)$ | No change or <br> $<1.5$ <br> $(\mathrm{n}=26)$ | $1.5-2.0$ fold <br> increase <br> $(\mathrm{n}=11)$ | $\geq 2.0$ fold <br> increase <br> $(\mathrm{n}=15)$ | P-value |
| :---: | :---: | :---: | :---: | :---: | :---: |
| CR | $3(5.8 \%)$ | $1(3.8 \%)$ | $1(9.1 \%)$ | $1(6.7 \%)$ | 0.673 |
| PR | $26(50.0 \%)$ | $14(53.8 \%)$ | $6(54.5 \%)$ | $6(40.0 \%)$ |  |
| SD | $19(36.5 \%)$ | $10(38.5 \%)$ | $3(27.3 \%)$ | $6(40.0 \%)$ |  |
| PD | $4(7.7 \%)$ | $1(3.8 \%)$ | $1(9.1 \%)$ | $2(13.3 \%)$ |  |

## Supplementary figure 1. Survival outcomes according to IL-10 changes.

PFS (A) and OS (B) of the patient with advanced RCC according to the C2D1/Baseline: No change or $<1.5$ fold ( $\mathrm{n}=26$ ), 1.5-2.0 fold increase ( $\mathrm{n}=11$ ), and $\geq 2.0$ fold increase ( $\mathrm{n}=15$ ). Pvalues were calculated using the log-rank test.
A
B


